Clinical Trial Update: Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections. [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating Amphotericin B in Optisol-GS to prevent post-keratoplasty fungal infections was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Dystrophy

Drugs mentioned

• Amphotericin B (Amphotericin B)
• Optisol-GS

Snippet

Sponsor: Cornea Research Foundation of America | Conditions: Fuchs' Endothelial Dystrophy | Phase 2, Phase 3 | Status: WITHDRAWN